Skip to main content
Clinical Trials/NCT01936727
NCT01936727
Completed
Not Applicable

Comparison of Two Phacoemulsification-methods: EasyTip 2.2mm vs. Infusion Assisted EasyTip 2.2mm

Medical University of Vienna1 site in 1 country50 target enrollmentStarted: December 2011Last updated:
ConditionsCataracts

Overview

Phase
Not Applicable
Status
Completed
Enrollment
50
Locations
1
Primary Endpoint
phacoemulsification time

Overview

Brief Summary

The aim of this study was to compare the intraoperative efficiency, safety and postoperative outcomes of cataract surgery with two different "high-fluidic" settings.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
50 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • bilateral age-related cataract
  • good overall physical constitution

Exclusion Criteria

  • previous intraocular surgery or ocular trauma
  • previous corneal pathology
  • previous endothelial cell count \<1200
  • diabetic retinopathy and any other severe retinal pathology that would make a postoperative visual acuity of 20/40 (decimal equivalent = 0.5) or better unlikely
  • intraocular complication like posterior capsular
  • postoperative comlpications (e.g. postoperative uveitis)

Outcomes

Primary Outcomes

phacoemulsification time

Time Frame: intraoperative

time spent for the phacoemulsification process was the phacoemulsification tip time (PTT) needed to divide the nucleus and the PTT needed to conquer it

effective phacoemulsification time

Time Frame: intraoperativ

time in seconds required had 100% power been used throughout the phacoemulsification process documented for the separation of the nucleus (divide) and the aspiration of the quadrants (conquer)

fluid volume

Time Frame: intraoperativ

amount of BSS used for dividing and conquering

Secondary Outcomes

  • postoperative corneal oedema(1 day, 1 week, 6 months)
  • postoperative endotheial cell loss(6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Rupert Menapace

Ao.Univ.-Prof. Dr.med.univ.

Medical University of Vienna

Study Sites (1)

Loading locations...

Similar Trials